iBio
IBIO
55 hedge funds and large institutions have $60.8M invested in iBio in 2026 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 12 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
65% more capital invested
Capital invested by funds: $36.9M → $60.8M (+$23.9M)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
13.69% more ownership
Funds ownership: 56.24% → 69.93% (+14%)
6% more funds holding
Funds holding: 52 → 55 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.38M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.89M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$4.65M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$3.28M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.01M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.47M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$784K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$169K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$129K |
IBIO Hedge Fund Activity: Q2 2026 in Review
55 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2026, worth a combined $60.8M — up 65% from $36.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IBIO positions and 12 closed out — a net gain of 4 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $6.38M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.01M sold.
- 55 institutional investors held iBio (IBIO) as of Q2 2026, up from 52 in Q1 2026.
- Funds reported $60.8M of iBio stock for Q2 2026, up 65% quarter-over-quarter.
- 16 funds opened new iBio positions in Q2 2026 and 12 closed out, a net change of +4 holders.
- The largest iBio buyer in Q2 2026 was Cormorant Asset Management, an estimated $6.38M added.
- The largest iBio seller in Q2 2026 was EcoR1 Capital, an estimated $3.01M sold.
Based on aggregated 13F filings for Q2 2026.